IDEXX LABORATORIES INC /DE

IDXX - CIK 0000874716

Market cap$43.93 B

Rank#351

SEC filings2,148

IDEXX LABORATORIES INC /DE trades as IDXX and has a market capitalization of $43.93 B, making it the #351 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $4.30B, up 10.4% from the prior year and net income of $1.06B. This page tracks IDEXX LABORATORIES INC /DE through 2,148 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$4.30BFY 2025

Net income (latest FY)$1.06BFY 2025

Operating cash flow (latest FY)$1.18BFY 2025

Total assets (latest FY)$3.35BFY 2025

Gross margin61.8%latest FY

Net margin24.6%latest FY

Financial performance

Over the last 9 fiscal years IDEXX LABORATORIES INC /DE's revenue grew from $1.78B to $4.30B, a compound annual growth rate of 10.3%. Net profit margin expanded from 12.5% to 24.6% over the same period - every figure below comes from the company's audited annual filings.

IDXX annual revenueView details

Key statistics

Market cap: $43.93 B
Share price (derived)market cap / shares outstanding: $556.94
P/E ratio (trailing FY): 41.5
EPS (diluted)FY 2025: $13.08
Shares outstandingas of 2026-04-30: 0.08B
Total equityas of 2026-03-31: $1.56B
Return on equity: 68.1%
Long-term debtas of 2026-03-31: $299.85M

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-05-20
Major company event	8-K	2026-05-15
Insider trade	4	2026-05-14
Insider trade	4	2026-05-14
Insider trade	4	2026-05-14
Insider trade	4	2026-05-14
Insider trade	4	2026-05-14
Insider trade	4	2026-05-14

Browse the full filing history (2,148 filings)

Recent press releases

IDEXX Laboratories Announces First Quarter Results
Raises 2026 EPS outlook to $14.45 - $14.90, reflecting an increase of $0.13 compared to prior guidance midpoint, supported by expectations for ...
IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 ...
Provides initial outlook for 2026 revenue guidance range of $4,632 million - $4,720 million, reflecting growth of 7.6% - 9.6% reported and 7.0% ...
IDEXX Laboratories Announces Third Quarter Results
Delivers EPS of $3.40, an increase of 21% as reported and 15% on a comparable basis, including operating margin expansion of 100 basis points as ...

Similar companies

The largest companies sharing IDEXX LABORATORIES INC /DE's SEC industry classification (in vitro & in vivo diagnostic substances).

LNTHLantheus Holdings, Inc.$6.53 B IDXX vs LNTH

CLDXCelldex Therapeutics, Inc.$2.30 B IDXX vs CLDX

NEOGNeogen Corporation$2.01 B IDXX vs NEOG

NTLAIntellia Therapeutics, Inc.$1.73 B IDXX vs NTLA

NNNNAnbio Biotechnology$1.50 B IDXX vs NNNN

Frequently asked questions

What is IDEXX LABORATORIES INC /DE's market cap?

IDEXX LABORATORIES INC /DE (IDXX) has a market capitalization of $43.93 B as of 2026-06-10, ranking #351 among US-listed companies.

How much revenue does IDEXX LABORATORIES INC /DE make?

IDEXX LABORATORIES INC /DE reported revenue of $4.30B for fiscal year 2025, an increase of 10.4% year over year.

Is IDEXX LABORATORIES INC /DE profitable?

Yes. IDEXX LABORATORIES INC /DE reported net income of $1.06B in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.